Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer .
Filed returns
111
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2022 | Pfizer | Taxation | Proposed changes to global taxation at the OECD and by the U.S. administration (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Economic Development and Industry | COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) | 17 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | Pfizer COVID-19 anti-viral treatment (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | PMB re orphan medicines, Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2021 (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Health | Update on Pfizer COVID 19 antiviral treatment and processes in ensuring availability of the treatment in Ireland (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Health | PMB in relation to reimbursement of orphan medicines Health (Pricing and Supply of Medical Goods) (Amendment) Bill 2021 (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Economic Development and Industry | Proposed COVID-19 Trips waiver (Public policy or programme) | 12 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | Agreement on Pricing and Supply of Medicines 2021 - 2025 (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Economic Development and Industry | Proposed COVID-19 Trips waiver (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Taxation | Proposed changes to global taxation at the OECD and by the U.S. administration (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| May–Aug 2021 | Pfizer | EU Affairs | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Taxation | There are proposed changes to global taxation at the OECD and by the U.S. administration (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Supply of Pfizer COVID-19 vaccine including Ireland volumes; expansion of manufacturing capacity to include Grange Castle site and Pfizer colleague vaccination programme (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Outline Ireland's medicine reimbursement system and timelines compared with other countries (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Economic Development and Industry | Globally, debate is underway in relation to a COVID-19 vaccines IP waiver (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Trade | Highlight importance of IP rights and understand EP actions on possible TRIPS waiver proposal; discuss EU Pharmaceutical Strategy and importance of free trade in medicines and vaccines. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Highlight Ireland's slowness in reimbursing new medicines for Irish patients compared with other EU countries (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Economic Development and Industry | Highlight the importance of pharmaceutical manufacturing activity being deemed essential activity to ensure the continued operation of Pfizer manufacturing sites wh (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | EU Affairs | Highlight Pfizer concerns re proposed EU vaccine export restrictions and how this could impact Pfizer's ability to manufacture the COVID 19 vaccine and provide supply globally (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2020 | Pfizer | Economic Development and Industry | Highlight the importance of Ireland's pro innovation policies, including corporate tax policy, in ensuring continued investment in Irish operations (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Pfizer | Health | Highlight Ireland's slowness in reimbursing innovative medicines compared to other European countries and outline factors contributing to this (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2020 | Pfizer | Health | Discussions in relation to Pfizer/BioNtech progress in development of a vaccine for COVID 19 (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Economic Development and Industry | Welcomed committment to corporation tax policy and a supportive environment for FDI as outlined in the Programme for Government (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Highlighted discussions on extension of industry Supply Agreement and the importance of ensuring expenditure is efficently managed to ensure Irish patients can access innovative medicines; welcomed plans to progress the… (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Provided information about Pfizer's research into a COVID-19 vaccine, meeting sought with MoH/DoH. (Public policy or programme) | 29 | On lobbying.ie |
| Jan–Apr 2020 | Pfizer | Economic Development and Industry | Highlighted the need for pharmaceutical manufacturing to continue to ensure continuity of supply of medicines. Pfizer's Irish manufacturing operations are involved in the supply of a wide range of medicines and vaccines… (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2019 | Pfizer | Economic Development and Industry | Global competition for foreign direct investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2019 | Pfizer | Health | Ireland has become one of the slowest countries in Europe to reimburse innovative medicines for patients, now ranking 16th out of 26th according to EFPIA. (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2019 | Pfizer | EU Affairs | The EU Commission is introducing legislation for an SPC (Supplementary Protection Certificate) ‘export exemption’; this would allow companies to manufacture products that have an SPC within the EU for export outside the… (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2018 | Pfizer | Health | Ireland has become one of the slowest countries in Europe to reimburse innovative medicines for patients, now ranking 16th out of 26th according to EFPIA. (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2018 | Pfizer | EU Affairs | The EU Commission is introducing legislation for an SPC (Supplementary Protection Certificate) ‘export exemption’; this would allow companies to manufacture products that have an SPC within the EU for export outside the… (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2018 | Pfizer | Taxation | Global competition for FDI and life sciences investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 21 | On lobbying.ie |
| Jan–Apr 2018 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Transport | The N28 road in Cork needs to be upgraded handle current traffic volumes and colleagues working at the Pfizer Ringaskiddy site are impacted by congestion. (Zoning or development) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Science Foundation Ireland has a research centre, INNATE which has been approved in principle but requires funding. The infrastructure and focus intended by INNATE would help upskill scientists and help translate early… (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | The Anti-Microbial Resistance Plan was due for publication in September 2017. The 3-year Plan covers the use of anti-microbial medicines in animal health and agriculture, and human health - taking a 'One Health'… (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer launched 'MBC: A Call to Action' to highlight the unmet needs of metastatic breast cancer patients. MBC is an advanced form of breast cancer where early detection does not improve survival. Even if diagnosed with… (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Economic Development and Industry | The Companies Act 2014 allowed for a Ministerial exemption from changing a company name to include the word 'unlimited' in the company name. This change would create significant burden for five of Pfizer's Irish… (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Economic Development and Industry | Global competition for foreign direct investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Health | Ireland has now become one of the slowest countries in Europe to reimburse innovative medicines for patients. HTA assessment is prolonged and decisions after HTA are exceptionally slow with the majority of medicines… (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metastatic breast cancer. Metastatic breast cancer is an advanced form of breast cancer where early detection unfortunately does not improve survival. Even if… (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Economic Development and Industry | The Companies Act 2014 allowed for a Ministerial exemption from changing a company name to include the word 'unlimited' in the company name. This change would create significant administrative and cost burden for five… (Legislation) | 11 | On lobbying.ie |
| Jan–Apr 2017 | Pfizer | Health | A Supply Agreement was negotiated in 2016 between the pharmaceutical industry and the state which provides 785m in savings over four years, ensures Irish on patent medicine prices are in line with 14 other EU countries… (Public policy or programme) | 7 | On lobbying.ie |
| Jan–Apr 2017 | Pfizer | Economic Development and Industry | Global competition for FDI and life sciences investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 7 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 56 | 50.5% | |
| EU Affairs | 21 | 18.9% | |
| Economic Development and Industry | 17 | 15.3% | |
| Taxation | 9 | 8.1% | |
| Trade | 4 | 3.6% | |
| Budgetary matters | 2 | 1.8% | |
| Energy and Natural Resources | 1 | 0.9% | |
| Transport | 1 | 0.9% |